Fortress Biotech, Inc. (FBIOP) Stock Price & Analysis
Fortress Biotech, Inc. (FBIOP) rose 0.00% to USD 20.2 as of June 10, 2026 at 12:09 UTC, according to Nexqual real-time market data.
FBIOP last closed at USD 20.2; the session ranged USD 20.02–20.4 on volume of 12,604 shares. Market capitalization is —, with a 52-week range of USD 6.27–21.23 (NCM). Source: Nexqual, June 10, 2026 at 12:09 UTC.
Key Statistics (as of June 10, 2026 at 12:09 UTC)
| Price | USD 20.2 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 20.2 |
| Open | USD 20.2 |
| Day Range | USD 20.02 – 20.4 |
| 52-Week Range | USD 6.27 – 21.23 |
| Volume | 12,604 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (FBIOP)
Nexqual's technical model rates FBIOP "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 12:09 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 77.37 (overbought) |
| vs SMA50 | Above (USD 15.26) |
| MACD | 1.75 (positive) |
Analyst Ratings (FBIOP)
Wall Street analysts rate FBIOP "None", per Nexqual as of June 10, 2026 at 12:09 UTC.
| Consensus Rating | None |
|---|
Earnings (FBIOP)
| Revenue Estimate | $18.30M |
|---|
Source: Nexqual, June 10, 2026 at 12:09 UTC.
Financials & Fundamentals (FBIOP)
| Total Revenue | $63.26M |
|---|---|
| Revenue Growth (YoY) | +6.30% |
| Gross Margin | +48.11% |
| Operating Margin | -29.78% |
| Profit Margin | +10.77% |
| ROE | -108.74% |
| Debt / Equity | 108.09 |
| Current Ratio | 2.49 |
| Total Cash | $79.38M |
| Total Debt | $67.22M |
| Free Cash Flow | $-47.29M |
Source: Nexqual, June 10, 2026 at 12:09 UTC.
Financial Health Score (FBIOP)
Nexqual rates Fortress Biotech, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 12:09 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 48%, operating -30% |
| Balance Sheet | Mixed — $79M cash vs $67M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$47M, burning cash |
| Efficiency | Critical — ROE -109%, ROA -26.6% |
Ownership (FBIOP)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 56.68M |
| Float | 22.38M |
Source: Nexqual, June 10, 2026 at 12:09 UTC.
Leadership (FBIOP)
Fortress Biotech, Inc. is led by Lindsay Allan Rosenwald (age 70), Executive Chairman, President & CEO, per Nexqual as of June 10, 2026 at 12:09 UTC.
| Executive Chairman, President & CEO | Lindsay Allan Rosenwald (age 70) |
|---|---|
| CFO & Head of Corporate Development | David Jin (age 34) |
| Chief Strategy Officer | Xiaoqin Lu (age 50) |
| Executive Vice Chairman of Strategic Development & Director | Michael S. Weiss Esq. (age 59) |
Major Backers & Investors (FBIOP)
Notable institutional backers of Fortress Biotech, Inc. include Shikiar Asset Management, Inc., according to Nexqual as of June 10, 2026 at 12:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shikiar Asset Management, Inc. | 0.44% |
Source: Nexqual, June 10, 2026 at 12:09 UTC.
From Fortress Biotech, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SOHOB | Sotherly Hotels Inc. - 8.0% Ser | USD 12.07 | ▲ 0% |
| OXLCM | Oxford Lane Capital Corp. - Pre | USD 25.38 | ▼ 0.1% |
| AIRTP | Air T, Inc. - Trust Preferred S | USD 18.09 | ▼ 7% |
| SOHOO | Sotherly Hotels Inc. - 7.875% S | USD 15.49 | ▲ 58.87% |
| OXLCO | Oxford Lane Capital Corp. - Pre | USD 24.22 | ▲ 0.37% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:09 UTC. This page is informational and not investment advice.